Instalab

Phoma Betae Mold IgE

Test
Find out if a lesser-known mold is quietly driving your allergy symptoms.

Should you take a Phoma Betae Mold IgE test?

This test is most useful if any of these apply to you.

Living With Mystery Allergy Symptoms
Your symptoms point to mold but the common panels came back clean, and you want to look beyond the usual suspects.
Gardening or Working Outdoors
You spend time around plants, soil, and decaying vegetation where this mold thrives, and want to know if your immune system is reacting.
Managing Asthma That Flares Outdoors
Your asthma worsens during peak outdoor mold seasons, and identifying specific mold triggers could sharpen your treatment plan.
Concerned About Indoor Mold Exposure
You live or work in a building with past water damage and want to map which molds your immune system has actually responded to.

About Phoma Betae Mold IgE

If you have stubborn allergy symptoms that flare during yard work, near gardens, or after exposure to decaying plant matter, a common mold like Alternaria or Cladosporium gets most of the attention. Phoma betae rarely makes the shortlist, even though it lives on the same kind of plant debris and can sensitize people in similar ways. This test looks for a specific antibody your immune system has built against this particular mold.

The number it returns tells you whether your immune system has flagged Phoma betae as a threat. That information helps you connect symptoms to a specific exposure rather than guessing among the dozens of molds in the air, and it gives an allergist a concrete target if avoidance or treatment is on the table.

What This Test Actually Measures

Your immune system makes IgE (immunoglobulin E, a type of antibody) when it has been exposed to something it now treats as foreign. When IgE specific to a mold like Phoma betae binds to immune cells called mast cells and basophils, future contact with that mold can trigger histamine release and the symptoms that follow: sneezing, congestion, itchy eyes, wheezing, or skin flares.

A positive result means your immune system has produced antibodies aimed at Phoma betae. That is what allergists call sensitization. Sensitization is not the same as a clinical allergy. Some people have measurable IgE without any symptoms when exposed. The test result is most useful when paired with a clear story of symptoms that line up with mold exposure.

Why Phoma Betae Specifically

Phoma betae is a plant fungus most commonly associated with beets and other crops, but its spores are released into the air alongside other outdoor molds. Standard mold panels often emphasize the heavyweights like Alternaria, Cladosporium, Aspergillus, and Penicillium. Less common molds can still drive real symptoms, and clinical research has shown that the mainstream allergen panels can miss sensitizations to underrepresented mold genera.

Older work measuring specific IgE to 16 widespread mold genera in 55 patients with suspected mold allergy found that 73% had detectable IgE to at least one mold, with multiple sensitivities most often reflecting separate sensitizations rather than cross-reactivity. That research argued that less commonly tested molds had been underestimated as allergens, which is the rationale for testing specific genera like Phoma betae rather than relying only on a generic mold mix.

What Elevated Levels Are Linked To

Research specifically on Phoma betae IgE in human disease is limited. Most of what is known about mold-specific IgE in general comes from studies of more widely tested molds. The patterns below come from research on related mold allergens, not Phoma betae directly, but they illustrate the conditions where mold-specific IgE most often shows up.

Allergic Rhinitis and Asthma

In a study of 229 adults with allergic rhinitis driven by mold sensitization, mold allergy was linked to a greater predisposition for bronchial asthma and higher concentrations of nasal nitric oxide, a marker of airway inflammation. In a separate analysis of patients with allergic rhinitis and asthma, sensitization to Alternaria alternata (13.07%) and Cladosporium herbarum (6.7%) was most common and tracked with greater disease severity. Phoma betae was not specifically reported in these studies, but it belongs to the same broad category of outdoor mold allergens that contribute to upper and lower airway symptoms.

Atopic Dermatitis

Among 100 adults with atopic dermatitis tested with a multiplex IgE assay, sensitization to mold components from Alternaria, Cladosporium, Aspergillus, and the yeasts Malassezia and Candida correlated with more severe atopic dermatitis. Sensitization to Cladosporium components and the Alternaria component Alt a 6 was also more frequent in patients who also had asthma. This research did not include Phoma betae, but it supports the broader pattern that mold-specific IgE often shows up alongside more severe allergic skin and airway disease.

Hypersensitivity From Mold Exposure

Research on dampness and mold hypersensitivity syndrome found that workers in a documented water-damaged building had higher mold-specific IgE against strains isolated from that building compared with controls. IgE measured against an unrelated mold strain from a different building did not separate the two groups. The takeaway is that mold-specific IgE is most informative when the test allergen actually matches what someone has been exposed to. If you are around plants, soil, or decaying vegetation where Phoma betae thrives, testing for it specifically can fill a gap that standard panels leave open.

Reference Ranges

Phoma betae IgE does not have a published reference range tied to outcomes the way LDL or HbA1c does. Most labs report results using the general allergen-specific IgE classification system, which groups results by concentration in kilounits per liter (kU/L). These class breakpoints come from broad allergen-specific IgE testing literature, not from studies of Phoma betae specifically. They are orientation, not a target. A positive result must be interpreted alongside symptoms and exposure history.

ClassRange (kU/L)What It Suggests
0Less than 0.10Below detection. No measurable sensitization.
I0.10 to 0.70Low level sensitization. Often clinically silent on its own.
II to III0.70 to 17.5Moderate sensitization. More likely to align with symptoms when exposure is real.
IV to VIAbove 17.5High to very high sensitization. Strong correlation with clinical reactivity in symptomatic people.

Compare your results within the same lab over time. Different platforms (such as ImmunoCAP, Immulite, and ALEX2) can produce different absolute values, and switching labs makes serial comparison unreliable.

Why a Single Reading Is Not Enough

Allergen-specific IgE is not static. Levels can rise during peak mold seasons, fall after a year of avoidance, and shift in response to allergen immunotherapy. A single number tells you whether your immune system currently recognizes Phoma betae. A trend tells you whether that recognition is growing, shrinking, or holding steady, and whether what you are doing about it is working.

Get a baseline. If you start an intervention like immunotherapy or biologic therapy, retest in 6 to 12 months to see how the antibody profile is shifting. If you are simply tracking exposure, an annual check during the same season is reasonable. Always use the same lab and assay for comparisons.

What to Do With an Abnormal Result

A positive Phoma betae IgE on its own does not require treatment. The next step depends on whether your symptoms map onto exposure to plant material, soil, gardening, agriculture, or damp environments where this mold can grow. Bring your result to an allergist who can correlate the number with skin testing or component-resolved diagnostics, and who can rule out cross-reactivity with related molds in the Pleosporaceae family.

Companion tests worth considering alongside this one include total IgE (to put the specific result in context), IgE to the more common molds (Alternaria, Cladosporium, Aspergillus, Penicillium) to map your overall mold profile, and a tryptase level if you have had severe systemic reactions. If your symptoms include chronic cough, wheeze, or recurring sinus issues, an allergy and pulmonology workup may be the right path.

When Results Can Be Misleading

  • Cross-reactivity with related molds: the Pleosporaceae family includes Alternaria and other molds that share allergenic proteins. A positive Phoma betae result may sometimes reflect cross-reactivity rather than independent sensitization.
  • Recent allergen exposure: levels may run higher shortly after an intense exposure season. A test taken in peak outdoor mold season can read differently than one taken in winter.
  • Lab-to-lab variation: different assay platforms produce different absolute values for the same blood sample. Switching labs mid-series can manufacture an apparent change that reflects the assay, not your biology.
  • Sensitization without symptoms: a positive IgE result is not by itself a diagnosis of allergy. Around one in four people with a positive test will not have clinical symptoms when exposed to that allergen.

What Moves This Biomarker

Evidence-backed interventions that affect your Phoma Betae Mold IgE level

Decrease
Omalizumab (anti-IgE biologic)
Omalizumab binds free IgE and reduces IgE available to bind mast cells and basophils. Meta-analyses in respiratory and food allergy show that adding omalizumab to immunotherapy raises desensitization rates, gets more patients to maintenance doses, and reduces severe reactions. The effect is on IgE-driven biology overall rather than on Phoma betae specifically, but the same mechanism applies to mold-specific sensitization.
MedicationStrong Evidence
Decrease
Dupilumab (IL-4 receptor blocker)
Dupilumab blocks the type-2 inflammation pathway that drives IgE production. In 16 adults with chronic sinus disease and aeroallergen sensitization, dupilumab reduced serum allergen-specific IgE to birch (Bet v 1) by 34.9% and to grass (Phl p 1) by 28.7% over 6 months, with even larger drops in nasal fluid. Total IgE also fell significantly. This is evidence about birch and grass IgE, not Phoma betae specifically, but the underlying pathway is shared across allergens.
MedicationStrong Evidence
Decrease
Allergen immunotherapy (subcutaneous or sublingual)
Allergen immunotherapy is the only intervention that consistently changes the underlying immune response driving allergen-specific IgE. Over months to years, it lowers allergen-specific IgE and raises blocking antibodies (IgG4 and IgA) that compete with IgE for the allergen. In a study of 55 house dust mite-allergic asthma patients, immunotherapy increased allergen-specific IgG4 by 12 weeks and produced serum that significantly inhibited basophil activation. Direct evidence specifically for Phoma betae immunotherapy is limited, since standardized extracts mainly exist for the more common molds like Alternaria.
MedicationModerate Evidence
Decrease
Oral itraconazole for severe asthma with fungal sensitization
In 58 adults with severe asthma and sensitization to at least one fungus, itraconazole 200 mg twice daily for 32 weeks reduced total serum IgE by 27% versus a 12% increase on placebo, alongside better quality of life and morning peak flow. The trial measured total IgE and fungal sensitization broadly, not Phoma betae IgE specifically, so the effect on Phoma betae is inferred from the class.
MedicationModerate Evidence
Decrease
Allergen avoidance and environmental control
Reducing exposure to indoor mold sources (damp basements, leaks, organic debris, plant matter) is the foundational behavioral approach for any mold sensitization. Evidence for quantified reductions in mold-specific IgE is limited and heterogeneous, but lower exposure typically reduces symptoms and may slowly lower IgE over time. For Phoma betae, this includes minimizing contact with decaying plant material, garden debris, and damp soil.
LifestyleModest Evidence

Frequently Asked Questions

References

13 studies
  1. Denning D, O'driscoll B, Powell G, Chew F, Atherton G, Vyas a, Miles J, Morris J, Niven RAmerican Journal of Respiratory and Critical Care Medicine2008
  2. Feng M, Zeng X, Su Q, Shi X, Xian M, Qin R, Li JFrontiers in Cell and Developmental Biology2020
  3. Campion N, Doralt a, Lupinek C, Berger M, Poglitsch K, Brugger J, Quint T, Gangl K, Sinz C, Bartosik T, Liu D, Landegger LD, Tu a, Stanek V, Berger U, Bangert C, Schneider S, Eckl-dorna JAllergy2023